Latest Protein-bound paclitaxel Stories
Abraxis BioScience has received approval from the China State Food and Drug Administration to market Abraxane paclitaxel for injection for the treatment of breast cancer after failure of standard chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy.
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. (NASDAQ:ABBI), an integra
LONDON (Reuters) - Anglo-Swedish drugmaker AstraZeneca Plc said on Thursday it had agreed to sell its U.S. anesthetics and analgesic product portfolio to Abraxis BioScience for $350 million.
- The parings of haberdine; also, any kind of fragments.